Ranibizumab
Indication
Macular Oedema - retinal vein occlusion (NICE TA283)
NICE TA283 - Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Red
Brand:
Lucentis®
Nice TA:
283
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Eye
Background
CCGs should only fund treatment obtained through the patient access scheme